Founder Mina Sooch Issues Open Letter to Opus Genetics Stockholders Following Withdrawal of the Restore Value Slate Amid Dilutive Financing and Governance Concerns

Board Timed Highly Dilutive Financing to Close on the Record Date for the Annual Meeting, Tilting the Vote and Forcing the Withdrawal of the Restore Value Slate Second Major Transaction in Six Months Undertaken Without Stockholder Input with Significant Equity Dilution Company's Shifting Narrative on APX3330 in Disclosures Raises Questions of Omissions, Consistency, and Integrity of Strategic Communications FDA-Approved RYZUMVI™ Received Minimal Valuation in Both the Merger and Financing Transactions Desp ...